
"Sector" = median of Healthcare across 84 companies
West Pharmaceutical Services Inc. is a global leader in designing and manufacturing innovative containment and delivery systems for injectable drugs and healthcare products. The company specializes in components such as stoppers, seals, vials, syringes, and cartridges, as well as advanced drug delivery systems like auto-injectors and safety devices. Its products are critical for maintaining drug sterility and integrity, particularly for biologics, vaccines, and high-value therapies.
West generates revenue primarily through two segments: Proprietary Products (about 80% of sales) and Contract-Manufactured Products. Proprietary Products includes its core packaging components and drug delivery systems, while Contract-Manufactured Products offers custom manufacturing services for pharmaceutical and medical device companies. The company's high-margin, recurring revenue from consumables is complemented by long-term supply agreements with major pharmaceutical firms.
Operating in the Medical Instruments & Supplies industry within the Healthcare sector, West holds a dominant position in the global market for elastomeric components and drug containment systems. It competes with companies like AptarGroup, Gerresheimer, and Becton Dickinson, but differentiates itself through proprietary technologies, rigorous quality standards, and deep expertise in regulatory compliance. Its strong brand and customer relationships create significant barriers to entry.
West's primary customers are pharmaceutical, biotechnology, and generic drug manufacturers, as well as contract research organizations and hospitals. Geographically, revenue is well-diversified: the Americas account for roughly 50% of sales, Europe/Middle East/Africa about 35%, and Asia-Pacific around 15%. The company benefits from the growing demand for injectable drugs, especially biologics and vaccines, and its products are used in over 100 countries.
An auto-generated descriptive profile based on company data, for informational purposes only.
No 24-hour summary has been generated yet.
Latest saved period: March 2026 · 2026-03-31
Cash dividends by ex-date, not an investment recommendation.
| Ex-date | Amount | Payment date | Period |
|---|---|---|---|
| Apr 29, 2026 | $0.22 | May 6, 2026 | Quarterly |
| Jan 28, 2026 | $0.22 | Feb 4, 2026 | Quarterly |
| Nov 12, 2025 | $0.22 | Nov 19, 2025 | Quarterly |
| Jul 30, 2025 | $0.21 | Aug 6, 2025 | Quarterly |
| Apr 30, 2025 | $0.21 | May 7, 2025 | Quarterly |
| Feb 7, 2025 | $0.21 | Feb 11, 2025 | Quarterly |
| Nov 13, 2024 | $0.21 | Nov 20, 2024 | Quarterly |
| Jul 31, 2024 | $0.20 | Aug 7, 2024 | Quarterly |
| Apr 23, 2024 | $0.20 | May 1, 2024 | Quarterly |
| Jan 30, 2024 | $0.20 | Feb 7, 2024 | Quarterly |
| Nov 7, 2023 | $0.20 | Nov 15, 2023 | Quarterly |
| Jul 25, 2023 | $0.19 | Aug 2, 2023 | Quarterly |
| Apr 25, 2023 | $0.19 | May 3, 2023 | Quarterly |
| Jan 24, 2023 | $0.19 | Feb 1, 2023 | Quarterly |
| Nov 8, 2022 | $0.19 | Nov 16, 2022 | Quarterly |
| Jul 19, 2022 | $0.18 | Aug 3, 2022 | Quarterly |
| Apr 19, 2022 | $0.18 | May 4, 2022 | Quarterly |
| Jan 18, 2022 | $0.18 | Feb 2, 2022 | Quarterly |
| Nov 9, 2021 | $0.18 | Nov 17, 2021 | Quarterly |
| Jul 20, 2021 | $0.17 | Aug 4, 2021 | Quarterly |
| Apr 20, 2021 | $0.17 | May 5, 2021 | Quarterly |
| Jan 19, 2021 | $0.17 | Feb 3, 2021 | Quarterly |
| Nov 9, 2020 | $0.17 | Nov 18, 2020 | Quarterly |
| Jul 28, 2020 | $0.16 | Aug 5, 2020 | Quarterly |
Wrqti brings West Pharmaceutical Services, I data into one page covering available price, financial statements, valuation ratios, margins, cash-flow metrics, news, and alerts. This page helps you understand the numbers and is not a buy or sell recommendation.
Companies in the Healthcare sector you can compare with West Pharmaceutical Services, I:
When available, the page shows quarterly and annual statements plus ratios such as PE, price to book, profit margin, and free cash flow. Latest financial period shown: March 2026.
Wrqti content depends on available data and third-party sources and may include delays or errors. Review official company filings and consult a licensed financial advisor before making investment decisions. Read the data methodology.